BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Yearly Reports

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Corporate Presentation

SACHS 7th Annual Immuno-Oncology Innovation Forum 2021

18 May 2021

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

23.98
At close: 4:25PM CEST
--0.1 (--0.42%)
Share Price Chart

News

Latest News

BERGENBIO PRESENTS ENCOURAGING UPDATED PRELIMINARY DATA FROM PHASE II STUDY IN RELAPSED AML PATIENTS AT EHA VIRTUAL MEETING

BERGENBIO ANNOUNCES LATE-BREAKING ABSTRACT PRESENTATION AT ECCMID 2021

BERGENBIO RECEIVED FDA FAST-TRACK DESIGNATION FOR BEMCENTINIB / ANTI-PD-(L)1 COMBINATION IN NSCLC

More News

Scientific Presentations

EHA 2021, Dr. Sonja Loges et al.

11 June 2021

Read More

Annual Report 2020

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BERGENBIO TO PRESENT AT ABGSC SEMINAR

BERGENBIO PRESENTING AT SACHS 7TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM

BERGENBIO ASA: Webcast presentation

BERGENBIO ASA: Invitation to FIRST quarter 2021 results

14th Annual European Life Sciences (SACHS) CEO Forum

More Events

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.